🇺🇸 FDA
Pipeline program

REGN668

R668-AD-0914

Phase 1 mab completed

Quick answer

REGN668 for Dermatitis is a Phase 1 program (mab) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Dermatitis
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials